metformin has been researched along with Oligomenorrhea in 15 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Oligomenorrhea: Abnormally infrequent menstruation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to evaluate and compare the effects of spironolactone and spironolactone plus metformin treatments on body mass index (BMI), hirsutism score, hormone levels, and insulin resistance in women with polycystic ovary syndrome (PCOS)." | 9.22 | Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome. ( Acmaz, B; Diri, H; Karaburgu, S; Karaca, Z; Kelestimur, F; Tanriverdi, F; Unluhizarci, K, 2016) |
| "In LBW-PP girls, early metformin therapy was found to prevent or delay the development of hirsutism, androgen excess, oligomenorrhea, and PCOS more effectively than late metformin." | 9.15 | Early metformin therapy (age 8-12 years) in girls with precocious pubarche to reduce hirsutism, androgen excess, and oligomenorrhea in adolescence. ( de Zegher, F; Díaz, M; Ibáñez, L; López-Bermejo, A; Marcos, MV, 2011) |
| "To determine whether metformin would safely reduce the rate of first-trimester spontaneous abortion without teratogenicity in 19 women with the polycystic ovary syndrome (PCOS)." | 9.09 | Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. ( Cameron, D; Glueck, CJ; Phillips, H; Sieve-Smith, L; Wang, P, 2001) |
| "To investigate the effect of metformin on endometrial receptivity in women with polycystic ovary syndrome (PCOS)." | 7.91 | The Effect of Metformin on the Endometrium of Women with Polycystic Ovary Syndrome. ( Anifandis, G; Antonakis, PT; Dafopoulos, K; Daponte, A; Dragamestianos, C; Garas, A; Georgoulias, P; Kostopoulou, E; Makrigiannakis, A; Messini, CI; Messinis, IE; Zacharouli, K, 2019) |
| "This study evaluated the use of metformin as first line treatment for patients with polycystic ovary syndrome." | 7.74 | The use of metformin as first line treatment in polycystic ovary syndrome. ( Abbas, M; Gannon, M, 2008) |
| "The aim of this study was to evaluate and compare the effects of spironolactone and spironolactone plus metformin treatments on body mass index (BMI), hirsutism score, hormone levels, and insulin resistance in women with polycystic ovary syndrome (PCOS)." | 5.22 | Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome. ( Acmaz, B; Diri, H; Karaburgu, S; Karaca, Z; Kelestimur, F; Tanriverdi, F; Unluhizarci, K, 2016) |
| "In LBW-PP girls, early metformin therapy was found to prevent or delay the development of hirsutism, androgen excess, oligomenorrhea, and PCOS more effectively than late metformin." | 5.15 | Early metformin therapy (age 8-12 years) in girls with precocious pubarche to reduce hirsutism, androgen excess, and oligomenorrhea in adolescence. ( de Zegher, F; Díaz, M; Ibáñez, L; López-Bermejo, A; Marcos, MV, 2011) |
| "Despite the fact that treatment with Diane(35) Diario restored regular menstrual cycles in all the patients, whereas metformin only did so in 50% of them, serum ferritin levels decreased at 12 and 24 weeks of treatment only with metformin, in association with a marked increase in insulin sensitivity." | 5.12 | Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses. ( Alvarez-Blasco, F; Botella-Carretero, JI; Escobar-Morreale, HF; Luque-Ramírez, M; San Millán, JL; Sanchón, R, 2007) |
| "To determine whether metformin would safely reduce the rate of first-trimester spontaneous abortion without teratogenicity in 19 women with the polycystic ovary syndrome (PCOS)." | 5.09 | Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. ( Cameron, D; Glueck, CJ; Phillips, H; Sieve-Smith, L; Wang, P, 2001) |
| "To investigate the effect of metformin on endometrial receptivity in women with polycystic ovary syndrome (PCOS)." | 3.91 | The Effect of Metformin on the Endometrium of Women with Polycystic Ovary Syndrome. ( Anifandis, G; Antonakis, PT; Dafopoulos, K; Daponte, A; Dragamestianos, C; Garas, A; Georgoulias, P; Kostopoulou, E; Makrigiannakis, A; Messini, CI; Messinis, IE; Zacharouli, K, 2019) |
| "This study evaluated the use of metformin as first line treatment for patients with polycystic ovary syndrome." | 3.74 | The use of metformin as first line treatment in polycystic ovary syndrome. ( Abbas, M; Gannon, M, 2008) |
| "Metformin treatment was well tolerated and was accompanied by a marked drop in hirsutism score, insulin response to oral glucose tolerance test, free androgen index, and baseline testosterone, androstenedione, dehydroepiandrosterone, and dehydroepiandrosterone sulfate levels (all P < 0." | 2.69 | Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. ( de Zegher, F; Ibáñez, L; Marcos, MV; Potau, N; Valls, C, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 8 (53.33) | 29.6817 |
| 2010's | 6 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ibáñez, L | 3 |
| Del Río, L | 1 |
| Díaz, M | 2 |
| Sebastiani, G | 1 |
| Pozo, ÓJ | 1 |
| López-Bermejo, A | 2 |
| de Zegher, F | 3 |
| Dragamestianos, C | 1 |
| Messini, CI | 1 |
| Antonakis, PT | 1 |
| Zacharouli, K | 1 |
| Kostopoulou, E | 1 |
| Makrigiannakis, A | 1 |
| Georgoulias, P | 1 |
| Anifandis, G | 1 |
| Dafopoulos, K | 1 |
| Garas, A | 1 |
| Daponte, A | 1 |
| Messinis, IE | 1 |
| Mokaberinejad, R | 1 |
| Rampisheh, Z | 1 |
| Aliasl, J | 1 |
| Akhtari, E | 1 |
| Diri, H | 1 |
| Karaburgu, S | 1 |
| Acmaz, B | 1 |
| Unluhizarci, K | 1 |
| Tanriverdi, F | 1 |
| Karaca, Z | 1 |
| Kelestimur, F | 1 |
| Langmár, Z | 1 |
| Marcos, MV | 2 |
| Dolfing, JG | 1 |
| Zwinderman, AH | 1 |
| Verboom-Perrels, JM | 1 |
| Schweitzer, DH | 1 |
| Dronavalli, S | 1 |
| Ehrmann, DA | 1 |
| Genazzani, AD | 1 |
| Lanzoni, C | 1 |
| Ricchieri, F | 1 |
| Baraldi, E | 1 |
| Casarosa, E | 1 |
| Jasonni, VM | 1 |
| Luque-Ramírez, M | 1 |
| Alvarez-Blasco, F | 1 |
| Botella-Carretero, JI | 1 |
| Sanchón, R | 1 |
| San Millán, JL | 1 |
| Escobar-Morreale, HF | 1 |
| Abbas, M | 1 |
| Gannon, M | 1 |
| Pirwany, IR | 1 |
| Yates, RW | 1 |
| Cameron, IT | 1 |
| Fleming, R | 2 |
| Valls, C | 1 |
| Potau, N | 1 |
| Glueck, CJ | 1 |
| Phillips, H | 1 |
| Cameron, D | 1 |
| Sieve-Smith, L | 1 |
| Wang, P | 1 |
| Hopkinson, ZE | 1 |
| Wallace, AM | 1 |
| Greer, IA | 1 |
| Sattar, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Trial of Metformin as Adjunct Therapy for Overweight Adolescents With Type 1 Diabetes[NCT01881828] | Phase 3 | 164 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| PCOS, Sleep Apnea and Metabolic Risk in Women[NCT00696111] | 80 participants (Anticipated) | Interventional | 2007-12-31 | Active, not recruiting | |||
| The Cardiovascular Risk Profile Associated With The Polycystic Ovary Syndrome And With Ovulatory Hyperandrogenism, And Its Changes During Treatment With Metformin Or Oral Contraceptives[NCT00428311] | Phase 4 | 50 participants | Interventional | 2004-04-30 | Completed | ||
| Effects of Metformin on Fertility and Pregnancy in Women With Polycystic Ovary Syndrome: a Randomized, Prospective, Placebo-controlled Multicenter Study[NCT00994812] | Phase 3 | 326 participants (Actual) | Interventional | 2002-08-31 | Completed | ||
| Effects of Inositol Alone or Associated With Alpha-lipoic Acid in Polycystic Ovary Syndrome Treatment[NCT04881851] | 90 participants (Anticipated) | Interventional | 2015-05-07 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in percent body fat (NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentage of change (Mean) |
|---|---|
| Metformin | -0 |
| Oral Placebo | 1 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentile (Mean) |
|---|---|
| Metformin | -1 |
| Oral Placebo | 1 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | insulin per kg (Mean) |
|---|---|
| Metformin | -0.1 |
| Oral Placebo | -0.0 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | centimeters (Mean) |
|---|---|
| Metformin | -0 |
| Oral Placebo | 1 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | mm Hg (Mean) | |
|---|---|---|
| Change in Systolic | Change in Diastolic | |
| Metformin | 0 | 0 |
| Oral Placebo | -0 | 0 |
Hemoglobin A1c is a measure of glycemic control over approximately the past 3 months (NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentage (Mean) | |
|---|---|---|
| HbA1c | Change from Baseline to 26 Weeks | |
| Metformin | 9.0 | 0.2 |
| Oral Placebo | 8.9 | 0.2 |
Hemoglobin A1c is a measure of glycemic control over approximately the past 3 months (NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| HbA1c Decrease ≥0.5% | HbA1c Increase ≥0.5% | HbA1c <7.5% | |
| Metformin | 19 | 44 | 3 |
| Oral Placebo | 18 | 35 | 4 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | mg/dL (Mean) | ||||
|---|---|---|---|---|---|
| Change in LDL | Change in VLDL | Change in HDL | Change in Triglycerides | Change in Total Cholesterol | |
| Metformin | -6 | -0 | -0 | 4 | -5 |
| Oral Placebo | 2 | 1 | -1 | 6 | 3 |
10 trials available for metformin and Oligomenorrhea
| Article | Year |
|---|---|
Normalizing Ovulation Rate by Preferential Reduction of Hepato-Visceral Fat in Adolescent Girls With Polycystic Ovary Syndrome.
Topics: Adolescent; Body Mass Index; Contraceptives, Oral, Combined; Drug Combinations; Ethinyl Estradiol; F | 2017 |
The comparison of fennel infusion plus dry cupping versus metformin in management of oligomenorrhoea in patients with polycystic ovary syndrome: a randomised clinical trial.
Topics: Acupuncture Therapy; Adult; Body Mass Index; Cupping Therapy; Dysmenorrhea; Female; Foeniculum; Huma | 2019 |
Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome.
Topics: Adolescent; Adult; Blood Glucose; Body Mass Index; Dehydroepiandrosterone Sulfate; Drug Therapy, Com | 2016 |
Early metformin therapy (age 8-12 years) in girls with precocious pubarche to reduce hirsutism, androgen excess, and oligomenorrhea in adolescence.
Topics: Adolescent; Child; Female; Follow-Up Studies; Hirsutism; Humans; Hyperandrogenism; Hypoglycemic Agen | 2011 |
Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia.
Topics: Adolescent; Adult; Amenorrhea; Female; Glucose Tolerance Test; Humans; Hyperandrogenism; Hyperinsuli | 2007 |
Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses.
Topics: Adolescent; Adult; Androgen Antagonists; Cyproterone Acetate; Drug Combinations; Ethinyl Estradiol; | 2007 |
Effects of the insulin sensitizing drug metformin on ovarian function, follicular growth and ovulation rate in obese women with oligomenorrhoea.
Topics: Adult; Endocrine Glands; Fasting; Female; Hormones; Humans; Insulin; Longitudinal Studies; Metformin | 1999 |
Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche.
Topics: Adolescent; Adult; Blood Glucose; Female; Hirsutism; Hormones; Humans; Hyperandrogenism; Hyperinsuli | 2000 |
Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adult; Birth Weight; Female; Health Status Indic | 2001 |
Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial.
Topics: Adult; Body Mass Index; Double-Blind Method; Female; Fertilization; Humans; Hypoglycemic Agents; Lip | 2002 |
5 other studies available for metformin and Oligomenorrhea
| Article | Year |
|---|---|
The Effect of Metformin on the Endometrium of Women with Polycystic Ovary Syndrome.
Topics: Adult; Corticotropin-Releasing Hormone; Drug Therapy, Combination; Endometrium; Estradiol; Estrogens | 2019 |
[Diagnosis and treatment of polycystic ovary syndrome].
Topics: Acne Vulgaris; Alopecia; Amenorrhea; Androgens; Clomiphene; Diabetes Complications; Diagnosis, Diffe | 2010 |
Early effects of metformin on glucose dynamics in women with oligoamenorrhea and regular menstrual cycles who were wearing a subcutaneous glucose sensor.
Topics: Blood Glucose; Blood Glucose Self-Monitoring; Female; Humans; Hypoglycemic Agents; Menstrual Cycle; | 2003 |
Pharmacologic therapy of polycystic ovary syndrome.
Topics: Amenorrhea; Contraceptives, Oral, Hormonal; Drug Therapy, Combination; Female; Humans; Hyperandrogen | 2007 |
The use of metformin as first line treatment in polycystic ovary syndrome.
Topics: Adolescent; Adult; Amenorrhea; Body Mass Index; Clomiphene; Female; Follicle Stimulating Hormone; Hi | 2008 |